Ashley Chan

Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

After radical prostatectomy, patients with prostate cancer treated with abiraterone acetate plus prednisone and apalutamide had improved outcomes without a significant impact on their health-related quality of life.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.